@RareCyte profile picture
RareCyte, Inc. @RareCyte

High-confidence spatial biology and liquid biopsy

Joined July 2016
  • Tweets 947
  • Following 141
  • Followers 368
Photos and videos
Dr. Tanjina Kader discusses her ovarian cancer research at Harvard Medical School and how her team maps spatial proteomics and chromosomal changes on the same tissue section. #BreastCancer #SpatialProteomics
0:36
44
#ASCO2026 poster utilizing the CyteFinder® Rare Cell Detection platform shows strong concordance of CTC Androgen Receptor and Synaptophysin expression via liquid biopsy with tissue defined neuroendocrine differentiation in prostate cancer. View poster ➡️ rarecyte.com/posters.html
58
How can we identify the minimal signature needed to bring spatial biology into clinical trials? 💡 Kevin Byrd, PhD, of @VCU, explains how his team connects RNA data to protein data, and then to H&E. Their goal is to uncover biomarkers with real clinical utility. #AACR2026 #AACR
0:37
50
💡As therapies enter clinical development, researchers need to understand how drugs are impacting the TME and whether intended biological effects are occurring within patient tissue. See 4 ways biopharma teams are using high-plex spatial proteomics➡️ rarecyte.com/blog-2026-06.02…
38
Successful Orion training at @UBC. 🚀 The Poh Lab is using the Orion spatial proteomics platform to map the tumor immune microenvironment in oral cancer. #SpatialBiology #SpatialProteomics
35
Real or cake? 🎂 It's a tough one, we know. It was great getting our team together this week and celebrating the launch of Orion HT! Check out Orion HT on our website to see how close this cake is to the real thing: development.rarecyte.com/ori…
18
What is the impact of circulating tumor cell testing in clinical research? Hear from @pashtoonkasi (City of Hope) on the insights that CTCs uniquely give you, and how they complement tissue-based and circulating tumor DNA approaches. #AACR26 #AACR2026 #LiquidBiopsy
1:44
3
6
4
940
📣 RareCyte announces launch of Orion HT and Orion LE systems, extending the Orion platform across the full continuum of translational research, from early assay development and validation through clinical trial execution. ➡️ Read the press release: rarecyte.com/news-2026.04.20…
38
This study demonstrates the feasibility and robust performance of the CDH17 CTC assay in blood and cerebrospinal fluid of a colorectal cancer patient. ☑️Powered by RareCyte's CyteFinder platform #AACR2026 #AACR26
Pashtoon Kasi MD, MS
@pashtoonkasi
Apr 20
#AACR26 See our work that challenges so many dogmas about #LiquidBiopsies for cancer. ⚫️Not just DNA🧬, CTCs👇🏽 ⚫️Not just blood, CSF🧠 ⚫️Not just prognostic, predictive🎯CDH17 ⚫️Kinetics🟰📉response CSF cytology was negative ➖ So many💡 🔗abstractsonline.com/pp8/#!/2… @OncoAlert
43
📍Swing by the RareCyte booth (1823) at #AACR2026 to experience Orion HT, the spatial proteomics platform designed for clinical scale. View RareCyte’s AACR program: rarecyte.com/upcoming-events… #AACR2026 #SpatialProteomics #SpatialBiology
0:17
13
RareCyte is heading to #AACR2026 in San Diego! Stop by booth #1823 to hear exciting news around advancing spatial proteomics for clinical research. See our full conference program: rarecyte.com/upcoming-events… Book a meeting with us: calendly.com/events-rarecyte… #AACR #SpatialBiology
18
17-plex single-round imaging of human gastric adenocarcinoma, acquired on the Orion platform. 📸 This image, courtesy of Shumpei Ishikawa, PhD, from @UTokyo_News is featured in the RareCyte 2026 Calendar. View all images featured this year’s calendar: rarecyte.com/2026calendar/
63
Biomarker depth with throughput. No compromises. Introducing Orion HT — 20-channel imaging and 30-slide walkaway automation built for large-scale translational and clinical programs. Learn more ➡️ rarecyte.com/orion-ht/?utm_s… #SpatialBiology #SpatialProteomics #OrionSpatial
26
Spatial Biology Services ➝ Spatial Biomarker Insights for Translational and Clinical Studies Analyze tissue biopsies with multiplexed biomarker panels at high throughput, unlocking valuable quantitative insights from large cohort studies. 💡 Learn more: rarecyte.com/partnerships/
26
Upcoming webinar on easy strategies for reliable spatial biomarker results, presented by Simon Goldstein (@ljiresearch). Key topics: ✅ Validating antibody performance ✅ Designing and optimizing multiplex panels ✅ Sample preparation tips Register here: rarecyte.com/webinar-masteri…
1
29
💡 #SpatialInsight: Hidradenitis suppurativa (HS) is a chronic, debilitating inflammatory skin disease. This @nyuniversity team examined the immune microenvironment within HS lesions. ➡️ Explore the interactive tissue atlas: s3.us-east-1.amazonaws.com/w… #Hidradenitis #Autoimmune
2
64
17-plex imaging of renal cell carcinoma, acquired on the Orion platform. 📸 This image, courtesy of Gaurav Shrestha, PhD from the @OhioState is featured in the RareCyte 2026 Calendar. ➡️ View all images from our Calendar Contest: rarecyte.com/2026calendar/?u… #RareCyteCalendar
1
74
💥 18-plex imaging of breast duct harboring ductal carcinoma, acquired on the Orion spatial biology platform. 📸 This image, courtesy of Aditi Sanjay Khatpe, Stanford University, is featured in the RareCyte 2026 Calendar. View all calendar images: rarecyte.com/2026calendar/
114
Hear how spatial proteomics could change clinical practice in the near future. Sandro Santagata @BrighamWomens is presenting at #SABCS25 on how multiplex protein analysis enables deeper, more efficient tumor profiling, going beyond single-marker IHC. ➡️ sabcs.org/events/translation…
88
Heading to #SABCS25 next week? Don’t miss Karthik Giridhar's (@MayoClinic) poster on using CTC enumeration and ER/HER2 phenotyping to predict progression-free and overall survival in metastatic breast cancer. 🔬 Powered by the RareCyte CyteFinder Platform #AACR #BreastCancer
76
Load more